Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
The latest annual World Preview 2018, Outlook to 2024 shows that orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market. The rare disease space is predicted to capture 20% of the total $1.2trn market in 2024.
Supporting this growth are the launches of novel therapies, including gene and cell therapies, as well as increased access to medicines globally.